Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
Regenerative medicine startup Pelage Pharmaceuticals has clinical data showing its small molecule activated hair follicle stem cells. GV led a Series A round that funded the UCLA spinout’s Phase 1 clinical trial and will also support Phase 2 testing this year.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
Check out news from Alpha Sophia, Wisedocs, Swift Medical, and Isaac Health.
Check out news from Harmony Health Foundation, Gratia Health, Pathway, Fortuna Health, and more.
Merck, Sanofi, and Eli Lilly joined the Series A financing of Therini Bio, a startup developing a drug that selectively targets fibrin as a way of reducing disease-driving inflammation in neurodegeneration and eye disorders such as diabetic macular edema. Therini is preparing to advance its lead program to clinical testing.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.
GV led Chroma Medicine's Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
Miach Orthopaedics — a medical device company focused on restoring torn ACLs instead of reconstructing them — recently received $40 million in funding. The capital will be used to expand the U.S. commercial rollout of the company's implantable device, which received FDA de novo clearance in 2020.
Taking inspiration from the success of drug cocktails that halt viral infections, startup IDRx aims to develop cancer drug combinations that stop tumor escape. The company, founded by serial entrepreneur Alexis Borisy, has set gastrointestinal stromal tumor (GIST) as its first disease target.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Exo recently partnered with Henry Ford Health to validate its software platform for point-of-care ultrasounds. The health system's physicians will work with the company to increase the platform's ease of use, as well as commercialize the mobile ultrasound device Exo is developing.
Tomorrow Health — a platform that makes it easier for patients, providers and payers to coordinate home-based care — closed a $60 million Series B funding round on Tuesday, bringing its total funding to date to $92.5 million. The startup will use the funds to expand its partnerships with payers, grow in new markets and further develop its technology.
Remote patient monitoring technology has been around for more than a decade, but health systems have had a difficult time scaling their programs. This is because the huge amount of data collected by RPM technology often creates more work for physicians, said Cadence CEO Chris Altchek.
Socially Determined, a healthcare analytics startup focused on social determinants of health insights, closed a $26 million funding round on Tuesday. It will used the funds to expand its customer base, which comprises health plans, health systems and life sciences organizations.
Medallion — a provider management platform that automates licensing, continuing education tracking, credentialing and compliance — has completed three funding rounds in one year. On Thursday, it closed a $35 million Series C round, which will be used to help the startup attract more hospital and health system customers.